Oncologic emergencies: Immune-based cancer therapies and complications

Brit Long, Elizabeth Brém, Alex Koyfman

Research output: Contribution to journalReview article

Abstract

Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from chemotherapy and radiation. This review evaluates immune-based therapies and their complications for emergency clinicians. Therapy complications include immune-related adverse events (irAE), cytokine release syndrome (CRS), autoimmune toxicity, and chimeric antigen receptor (CAR) T-cell-related encephalopathy syndrome (CRES). Immune-related adverse events are most commonly encountered with checkpoint inhibitors and include dermatologic complications, pneumonitis, colitis/diarrhea, hepatitis, and endocrinopathies. Less common irAEs include nephritis, myocardial injury, neurologic toxicity, ocular diseases, and musculoskeletal complications. CRS and CRES are more commonly associated with CAR T-cell therapy. CRS commonly presents with flu-like illness and symptoms resembling sepsis, but severe myocardial and pulmonary disease may occur. Critically ill patients require resuscitation, broad-spectrum antibiotics, and hematology/oncology consultation.

Original languageEnglish (US)
Pages (from-to)566-580
Number of pages15
JournalWestern Journal of Emergency Medicine
Volume21
Issue number3
DOIs
StatePublished - 2020

ASJC Scopus subject areas

  • Emergency Medicine

Fingerprint Dive into the research topics of 'Oncologic emergencies: Immune-based cancer therapies and complications'. Together they form a unique fingerprint.

  • Cite this